Aino Health (AINO) Q3 2025 earnings summary

Executive summary

• Achieved continued commercial momentum in Q3 2025, with EBITDA near breakeven and disciplined cash flow management.

• Signed two major new customer contracts, expanding active SaaS licenses to 107,000 from 96,000 in Q2 2025.

• Focused on high-quality onboarding, customer success, and stable collections to support recurring revenue.

Financial highlights

• Q3 2025 turnover was 5,838 TSEK, up from 5,712 TSEK in Q3 2024; nine-month turnover reached 20,686 TSEK, up from 17,941 TSEK year-over-year.

• Profit after financial items for Q3 2025 was -1,292 TSEK, an improvement from -1,504 TSEK in Q3 2024; nine-month loss narrowed to -2,433 TSEK from -6,464 TSEK.

• Operating result for Q3 2025 was -1,027 TSEK, compared to -1,327 TSEK in Q3 2024.

• Cash flow for Q3 2025 was -37 TSEK, compared to 1,319 TSEK in Q3 2024.

Outlook and guidance

• Priorities include successful implementation for new customers, expansion within existing accounts, and maintaining operational rigor.

• Strengthening pipeline and rising market awareness position the company for profitable advancement.